$1.5M
+$1.5M this year1 filing since 2026 · latest Equity filed
Akelos, Inc. is a clinical-stage biopharmaceutical company founded in 2018, focused on the development of novel, non-opioid therapeutics for neuropathic pain. The company is advancing first-in-class compounds that utilize a unique mechanism of action to address a significant unmet medical need in a large patient population.
What sets it apart
The company's key differentiator is its development of non-addictive, non-narcotic drugs that selectively inhibit the HCN1 channel. This novel approach aims to provide effective pain relief without the common side effects associated with existing treatments, such as opioids or SNRIs.
AKE-1018 is the company's primary lead drug candidate, an anti-hyperalgesic compound currently in preclinical development. It is designed to treat neuropathic pain by selectively inhibiting the activity of the HCN1 ion channel, representing a new approach to pain management.
